双相抑郁药物维持治疗的真实世界有效性:瑞典全国队列的个体内分析
该研究基于瑞典全国登记数据,纳入2006年1月1日至2021年12月31日确诊双相障碍的105 495人,采用个体内设计比较药物与因抑郁、躁狂及躯体原因住院的关联。仅锂盐单药与抑郁相关住院风险降低相关(aHR 0.75,95%CI 0.67-0.85),且头对头比较中优于抗抑郁药、抗精神病药、喹硫平和拉莫三嗪单药。作者结论支持锂盐作为双相障碍治疗的主干。
要点
- 仅用抗抑郁药(aHR 1.25)、仅用抗精神病药(aHR 1.39)及部分联合治疗与抑郁相关住院风险升高相关。
- 仅用锂盐与抑郁相关住院风险降低相关(aHR 0.75,95%CI 0.67-0.85)。
- 头对头比较中锂盐单药优于抗抑郁药、抗精神病药、拉莫三嗪和喹硫平单药。
核心结论
- 在个体内分析中,与未使用抗抑郁药、抗精神病药和心境稳定剂相比,锂盐是唯一与抑郁相关住院风险显著降低相关的特定单药治疗。
- 头对头分析中,锂盐单药较任何抗抑郁药、任何抗精神病药、喹硫平或拉莫三嗪单药风险降低超过30%。
- 锂盐也与最低的躯体原因住院风险相关(aHR 0.86,95%CI 0.80-0.93)。
- 作者结论支持将锂盐作为双相障碍治疗的主干。
研究设计与样本
- 基于瑞典全国登记(住院和专科门诊、病假和残疾养老金)的个体内分析,纳入2006年1月1日至2021年12月31日确诊双相障碍者。
- 共纳入105 495人,平均年龄44.2岁(SD 18.8),女性65 607人(62.2%),男性39 888人(37.8%)。
- 治疗期采用PRE2DUP方法建模,使用分层Cox回归模型计算调整风险比(aHR)及95%CI。
- 参照为未使用抗抑郁药、抗精神病药和心境稳定剂。
- 主要结局为抑郁相关住院,次要结局为躁狂相关和躯体原因住院;并进行了药物间头对头比较。
主要发现
- 仅用抗抑郁药与抑郁相关住院风险升高相关(aHR 1.25,95%CI 1.16-1.34)。
- 仅用抗精神病药与抑郁相关住院风险升高相关(aHR 1.39,95%CI 1.24-1.55)。
- 抗抑郁药-抗精神病药联合治疗与抑郁相关住院风险升高相关(aHR 1.28,95%CI 1.18-1.39)。
- 抗精神病药-心境稳定剂联合治疗与抑郁相关住院风险升高相关(aHR 1.13,95%CI 1.03-1.24)。
- 仅用心境稳定剂与抑郁相关住院风险降低相关(aHR 0.89,95%CI 0.81-0.98)。
关键数值与推荐
- 在特定单药治疗中,仅锂盐与抑郁相关住院风险降低相关(aHR 0.75,95%CI 0.67-0.85)。
- 头对头比较中,锂盐单药优于抗抑郁药单药(aHR 0.59,95%CI 0.51-0.68)。
- 头对头比较中,锂盐单药优于抗精神病药单药(aHR 0.54,95%CI 0.44-0.66)。
- 头对头比较中,锂盐单药优于拉莫三嗪单药(aHR 0.69,95%CI 0.53-0.91)。
- 头对头比较中,锂盐单药优于喹硫平单药(aHR 0.54,95%CI 0.41-0.71)。
临床怎么用
- 作者结论支持将锂盐作为双相障碍治疗的主干。
- 原文未据此给出其他临床推荐。
局限性
- 原文指出,由于药物通常在抑郁症状复现时才开始使用,以未用药为参照时所有治疗可能显得比实际效果差。
- 原文提到种族数据不可获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term add-on antidepressant use for bipolar depression remains controversial. This study aimed to investigate primarily the association between psychopharmacological treatments and hospitalisation (ie, hospital admission) for bipolar depression, and secondarily the association between psychopharmacological treatments and hospitalisation for bipolar mania and somatic reasons in a registry-based national Swedish cohort. METHODS: In this within-subject analysis, people diagnosed with bipolar disorder were identified from Swedish nationwide registers of inpatient and specialised outpatient care, sickness absence, and disability pension between Jan 1, 2006, and Dec 31, 2021. Data for hospitalisations, and antidepressant, antipsychotic, and mood stabiliser medication use were also retrieved from national databases. Treatment periods were modelled using the PRE2DUP method. Data were analysed with a within-individual design with stratified Cox Regression models, to eliminate selection bias when calculating adjusted hazard ratios (aHRs) and 95% CIs. The main outcome was hospitalisation due to depression and secondary outcomes were mania-related and somatic hospitalisations to address the risk-benefit ratio of antidepressant treatment. The reference was non-use of antidepressant, antipsychotic, and mood stabiliser medications. We also did head-to-head comparisons (ie, comparing different drug use periods within the same individual against each other) between medications to obtain results on comparative effectiveness while minimising confounding by indication. Ethnicity data were not available. People with related lived experience were involved in the research and writing process. FINDINGS: The study cohort included 105 495 individuals (mean age 44·2 years, SD 18·8; 65 607 [62·2%] women and 39 888 [37·8%] men). In medication class-based analyses, a higher risk of depression-related hospitalisation was associated with the use of antidepressant only (aHR 1·25, 95% CI 1·16-1·34), antipsychotic only (1·39, 1·24-1·55), antidepressant-antipsychotic combination (1·28, 1·18-1·39), and antipsychotic-mood stabiliser combination treatment (1·13, 1·03-1·24). By contrast, use of mood stabilisers only (0·89, 0·81-0·98) was associated with lower risk. For specific monotherapies, only lithium was associated with lower depression-related hospitalisation risk (0·75, 0·67-0·85). No specific antidepressant monotherapy was associated with reduced depression-related hospitalisation, while several antidepressants and antipsychotics were related to an increased risk. In head-to-head comparisons, lithium monotherapy was associated with a superior outcome compared with antidepressant monotherapy (0·59, 0·51-0·68), antipsychotic monotherapy (0·54, 0·44-0·66), lamotrigine monotherapy (0·69, 0·53-0·91), and quetiapine monotherapy (0·54, 0·41-0·71). Lithium was associated with the lowest risk of somatic hospitalisation (0·86, 0·80-0·93) when compared with non-use of antidepressants, antipsychotics, and mood stabilisers. Finally, antidepressant-only treatment (1·22, 1·03-1·44) was associated with increased risk of mania-related hospitalisation and other monotherapies and combinations were associated with a lower risk. INTERPRETATION: Since medications are typically started when depressive symptoms re-emerge, all treatments might appear less effective than they actually are when the reference is non-use of medication. Lithium was the only specific monotherapy with significantly reduced risk of depression-related hospitalisations when compared with non-use of antidepressants, antipsychotics, and mood stabilisers, and with more than 30% lower risk than any antidepressant, any antipsychotic, quetiapine, or lamotrigine monotherapy in the head-to-head analysis. Lithium was also associated with the lowest risk of somatic hospitalisation. Our findings supported the use of lithium as the mainstay of treatment in bipolar disorder. FUNDING: The Swedish Research Council for Health, Working Life and Welfare, FORTE (grant number 2021-01079).
引用
- Ermis C, Taipale H, Tanskanen A, et al. Real-world effectiveness of pharmacological maintenance treatment of bipolar depression: a within-subject analysis in a Swedish nationwide cohort. Lancet Psychiatry. 2025. PMID: 39922213. doi:10.1016/S2215-0366(24)00411-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。